These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 10770644)
1. Survival efficacy of the combination of the methioninase gene and methioninase in a lung cancer orthotopic model. Miki K; Xu M; An Z; Wang X; Yang M; Al-Refaie W; Sun X; Baranov E; Tan Y; Chishima T; Shimada H; Moossa AR; Hoffman RM Cancer Gene Ther; 2000 Feb; 7(2):332-8. PubMed ID: 10770644 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Tan Y; Sun X; Xu M; Tan X; Sasson A; Rashidi B; Han Q; Tan X; Wang X; An Z; Sun FX; Hoffman RM Clin Cancer Res; 1999 Aug; 5(8):2157-63. PubMed ID: 10473100 [TBL] [Abstract][Full Text] [Related]
3. Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment. Miki K; Al-Refaie W; Xu M; Jiang P; Tan Y; Bouvet M; Zhao M; Gupta A; Chishima T; Shimada H; Makuuchi M; Moossa AR; Hoffman RM Cancer Res; 2000 May; 60(10):2696-702. PubMed ID: 10825143 [TBL] [Abstract][Full Text] [Related]
4. Methioninase Gene Therapy. Hoffman RM; Miki K; Al-Refaie W; Xu M; Tan Y Methods Mol Biol; 2019; 1866():173-197. PubMed ID: 30725416 [TBL] [Abstract][Full Text] [Related]
5. Combination efficacy of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine. Gupta A; Miki K; Xu M; Yamamoto N; Moossa AR; Hoffman RM Anticancer Res; 2003; 23(2B):1181-8. PubMed ID: 12820369 [TBL] [Abstract][Full Text] [Related]
6. Overexpression and large-scale production of recombinant L-methionine-alpha-deamino-gamma-mercaptomethane-lyase for novel anticancer therapy. Tan Y; Xu M; Tan X; Tan X; Wang X; Saikawa Y; Nagahama T; Sun X; Lenz M; Hoffman RM Protein Expr Purif; 1997 Mar; 9(2):233-45. PubMed ID: 9056489 [TBL] [Abstract][Full Text] [Related]
7. Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase. Yoshioka T; Wada T; Uchida N; Maki H; Yoshida H; Ide N; Kasai H; Hojo K; Shono K; Maekawa R; Yagi S; Hoffman RM; Sugita K Cancer Res; 1998 Jun; 58(12):2583-7. PubMed ID: 9635582 [TBL] [Abstract][Full Text] [Related]
8. Widespread skeletal metastatic potential of human lung cancer revealed by green fluorescent protein expression. Yang M; Hasegawa S; Jiang P; Wang X; Tan Y; Chishima T; Shimada H; Moossa AR; Hoffman RM Cancer Res; 1998 Oct; 58(19):4217-21. PubMed ID: 9766640 [TBL] [Abstract][Full Text] [Related]
9. Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5'-phosphate. Yang Z; Sun X; Li S; Tan Y; Wang X; Zhang N; Yagi S; Takakura T; Kobayashi Y; Takimoto A; Yoshioka T; Suginaka A; Frenkel EP; Hoffman RM Cancer Res; 2004 Aug; 64(16):5775-8. PubMed ID: 15313919 [TBL] [Abstract][Full Text] [Related]
10. Anticancer efficacy of methioninase in vivo. Tan Y; Xu M; Guo H; Sun X; Kubota T; Hoffman RM Anticancer Res; 1996; 16(6C):3931-6. PubMed ID: 9042315 [TBL] [Abstract][Full Text] [Related]
11. Polyethylene glycol conjugation of recombinant methioninase for cancer therapy. Tan Y; Sun X; Xu M; An Z; Tan X; Han Q; Miljkovic DA; Yang M; Hoffman RM Protein Expr Purif; 1998 Feb; 12(1):45-52. PubMed ID: 9473456 [TBL] [Abstract][Full Text] [Related]
12. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. Umeoka T; Kawashima T; Kagawa S; Teraishi F; Taki M; Nishizaki M; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T Cancer Res; 2004 Sep; 64(17):6259-65. PubMed ID: 15342413 [TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289 [TBL] [Abstract][Full Text] [Related]
14. Recombinant methioninase infusion reduces the biochemical endpoint of serum methionine with minimal toxicity in high-stage cancer patients. Tan Y; Zavala J; Han Q; Xu M; Sun X; Tan X; Tan X; Magana R; Geller J; Hoffman RM Anticancer Res; 1997; 17(5B):3857-60. PubMed ID: 9427792 [TBL] [Abstract][Full Text] [Related]
18. In vivo tumor delivery of the green fluorescent protein gene to report future occurrence of metastasis. Hasegawa S; Yang M; Chishima T; Miyagi Y; Shimada H; Moossa AR; Hoffman RM Cancer Gene Ther; 2000 Oct; 7(10):1336-40. PubMed ID: 11059691 [TBL] [Abstract][Full Text] [Related]
19. Treatment of cancer cells with methioninase produces DNA hypomethylation and increases DNA synthesis. Machover D; Zittoun J; Saffroy R; Broët P; Giraudier S; Magnaldo T; Goldschmidt E; Debuire B; Orrico M; Tan Y; Mishal Z; Chevallier O; Tonetti C; Jouault H; Ulusakarya A; Tanguy ML; Metzger G; Hoffman RM Cancer Res; 2002 Aug; 62(16):4685-9. PubMed ID: 12183426 [TBL] [Abstract][Full Text] [Related]
20. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer. Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]